Shopping Cart 0
Cart Subtotal
AED 0

Medivir AB (MVIR B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Medivir AB (Medivir) is a drug discovery and development company. The company offers protease inhibitor research and nucleotide or nucleoside science. It offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and RSV-infection. Medivir also provides products in partnership with other pharmaceutical companies for the disease areas of hepatitis C and labial herpes. The company's products are in Phase I and phase II development stages. It conducts research and development in the areas of infectious diseases, bone disorders and cancer. The company operates through a research unit in Huddinge, Sweden. Medvir is headquartered in Huddinge, Sweden.

Medivir AB (MVIR B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medivir AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Medivir AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Medivir AB, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Medivir Acquires Two Clinical Stage Oncology Programs from Tetralogic Pharma 11

Medivir Acquires Preclinical Research Stage Assets From Novadex Pharma 13

Partnerships 14

Medivir Enters into Research Agreement with GVK Biosciences 14

Medivir Enters into Development Agreement with Cancer Research Technology 15

Beactica Enters into Drug Discovery Agreement with Medivir 16

Medivir Enters Into Agreement With Swedish University of Agricultural Sciences To Develop Novel Drugs For Bacterial Infections 17

Licensing Agreements 18

AMR Centre Enters into Licensing Agreement with Medivir 18

Ascletis Pharma Enters into Licensing Agreement with Medivir for MIV-802 19

Trek Therapeutics Enters into Licensing Agreement with Medivir for MIV-802 20

Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 21

Ferrer And Medivir Enter Into Licensing Agreement For Commercialization Of Adasuve 22

Equity Offering 23

Medivir Raises USD19.7 Million in Private Placement of Shares 23

Asset Transactions 24

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 24

Acquisition 25

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 25

Unimedic Acquires Cross Pharma From Medivir For USD18.6 Million 26

Medivir AB-Key Competitors 27

Medivir AB-Key Employees 28

Medivir AB-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Jul 25, 2018: Medivir-interim report January-June 2018 30

Apr 27, 2018: Medivir-Interim Report January-March 2018 31

Feb 14, 2018: Medivir-Year End Report January-December 2017 32

Nov 03, 2017: Medivir appoints Erik Bjork as Chief Financial Officer 33

Oct 26, 2017: Medivir-Interim Report, January-September 2017 34

Jul 25, 2017: Medivir-interim report, January-June 2017 36

Apr 28, 2017: Medivir-Interim Report, January-March 2017 38

Feb 17, 2017: Medivir: Financial Statement, January-December 2016 40

Corporate Communications 42

Mar 15, 2018: The Nomination Committee's proposal for new Board of Directors to the Annual General Meeting 2018 42

Mar 14, 2018: Medivir Announces Departure of Chief Medical Officer 43

Jun 19, 2017: Medivir Appoints John Ohd as Chief Medical Officer 44

May 30, 2017: Medivir's CFO Will Leave his Position-Successor Recruitment Underway 45

Feb 09, 2017: Christine Lind new CEO of Medivir Effective 1 April 2017 46

Product News 47

Nov 08, 2017: Medivir Announces New Cancer Project, Leukotide, Derived from its in-house Nucleotide Platform 47

Clinical Trials 48

Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications 48

Other Significant Developments 49

Apr 04, 2018: Medivir's Annual Report for 2017 is published 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Medivir AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medivir AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Medivir AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medivir AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medivir AB, Deals By Therapy Area, 2012 to YTD 2018 9

Medivir AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Medivir Acquires Two Clinical Stage Oncology Programs from Tetralogic Pharma 11

Medivir Acquires Preclinical Research Stage Assets From Novadex Pharma 13

Medivir Enters into Research Agreement with GVK Biosciences 14

Medivir Enters into Development Agreement with Cancer Research Technology 15

Beactica Enters into Drug Discovery Agreement with Medivir 16

Medivir Enters Into Agreement With Swedish University of Agricultural Sciences To Develop Novel Drugs For Bacterial Infections 17

AMR Centre Enters into Licensing Agreement with Medivir 18

Ascletis Pharma Enters into Licensing Agreement with Medivir for MIV-802 19

Trek Therapeutics Enters into Licensing Agreement with Medivir for MIV-802 20

Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 21

Ferrer And Medivir Enter Into Licensing Agreement For Commercialization Of Adasuve 22

Medivir Raises USD19.7 Million in Private Placement of Shares 23

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 24

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 25

Unimedic Acquires Cross Pharma From Medivir For USD18.6 Million 26

Medivir AB, Key Competitors 27

Medivir AB, Key Employees 28

Medivir AB, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Medivir AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Medivir AB (Medivir) is a drug discovery and development company. The company offers protease inhibitor research and nucleotide or nucleoside science. It offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and RSV-infection. Medivir also provides products in partnership with other pharmaceutical companies for the disease areas of hepatitis C and labial herpes. The company's products are in Phase I and phase II development stages. It conducts research and development in the areas of infectious diseases, bone disorders and cancer. The company operates through a research unit in Huddinge, Sweden. Medvir is headquartered in Huddinge, Sweden.

Medivir AB (MVIR B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medivir AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Medivir AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Medivir AB, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Medivir Acquires Two Clinical Stage Oncology Programs from Tetralogic Pharma 11

Medivir Acquires Preclinical Research Stage Assets From Novadex Pharma 13

Partnerships 14

Medivir Enters into Research Agreement with GVK Biosciences 14

Medivir Enters into Development Agreement with Cancer Research Technology 15

Beactica Enters into Drug Discovery Agreement with Medivir 16

Medivir Enters Into Agreement With Swedish University of Agricultural Sciences To Develop Novel Drugs For Bacterial Infections 17

Licensing Agreements 18

AMR Centre Enters into Licensing Agreement with Medivir 18

Ascletis Pharma Enters into Licensing Agreement with Medivir for MIV-802 19

Trek Therapeutics Enters into Licensing Agreement with Medivir for MIV-802 20

Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 21

Ferrer And Medivir Enter Into Licensing Agreement For Commercialization Of Adasuve 22

Equity Offering 23

Medivir Raises USD19.7 Million in Private Placement of Shares 23

Asset Transactions 24

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 24

Acquisition 25

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 25

Unimedic Acquires Cross Pharma From Medivir For USD18.6 Million 26

Medivir AB-Key Competitors 27

Medivir AB-Key Employees 28

Medivir AB-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Jul 25, 2018: Medivir-interim report January-June 2018 30

Apr 27, 2018: Medivir-Interim Report January-March 2018 31

Feb 14, 2018: Medivir-Year End Report January-December 2017 32

Nov 03, 2017: Medivir appoints Erik Bjork as Chief Financial Officer 33

Oct 26, 2017: Medivir-Interim Report, January-September 2017 34

Jul 25, 2017: Medivir-interim report, January-June 2017 36

Apr 28, 2017: Medivir-Interim Report, January-March 2017 38

Feb 17, 2017: Medivir: Financial Statement, January-December 2016 40

Corporate Communications 42

Mar 15, 2018: The Nomination Committee's proposal for new Board of Directors to the Annual General Meeting 2018 42

Mar 14, 2018: Medivir Announces Departure of Chief Medical Officer 43

Jun 19, 2017: Medivir Appoints John Ohd as Chief Medical Officer 44

May 30, 2017: Medivir's CFO Will Leave his Position-Successor Recruitment Underway 45

Feb 09, 2017: Christine Lind new CEO of Medivir Effective 1 April 2017 46

Product News 47

Nov 08, 2017: Medivir Announces New Cancer Project, Leukotide, Derived from its in-house Nucleotide Platform 47

Clinical Trials 48

Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications 48

Other Significant Developments 49

Apr 04, 2018: Medivir's Annual Report for 2017 is published 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Medivir AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medivir AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medivir AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Medivir AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Medivir AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medivir AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medivir AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medivir AB, Deals By Therapy Area, 2012 to YTD 2018 9

Medivir AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Medivir Acquires Two Clinical Stage Oncology Programs from Tetralogic Pharma 11

Medivir Acquires Preclinical Research Stage Assets From Novadex Pharma 13

Medivir Enters into Research Agreement with GVK Biosciences 14

Medivir Enters into Development Agreement with Cancer Research Technology 15

Beactica Enters into Drug Discovery Agreement with Medivir 16

Medivir Enters Into Agreement With Swedish University of Agricultural Sciences To Develop Novel Drugs For Bacterial Infections 17

AMR Centre Enters into Licensing Agreement with Medivir 18

Ascletis Pharma Enters into Licensing Agreement with Medivir for MIV-802 19

Trek Therapeutics Enters into Licensing Agreement with Medivir for MIV-802 20

Medivir Enters into License Agreement with Boehringer Ingelheim International for Respiratory Syncytial Virus Drug Program 21

Ferrer And Medivir Enter Into Licensing Agreement For Commercialization Of Adasuve 22

Medivir Raises USD19.7 Million in Private Placement of Shares 23

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 24

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 25

Unimedic Acquires Cross Pharma From Medivir For USD18.6 Million 26

Medivir AB, Key Competitors 27

Medivir AB, Key Employees 28

Medivir AB, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Medivir AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.